| Summary: | 碩士 === 國立陽明大學 === 急重症醫學研究所 === 106 === Background: Severe meconium aspiration syndrome (MAS) may cause intractable respiratory failure in neonates. Targeting the renin-angiotensin system may be an effective way to treat such pulmonary dysfunction. Captopril has the potential to mitigate the severity of lung injury by inhibiting angiotensin-converting enzyme.
Methods: Twelve newborn piglets were intratracheally (IT) instilled with human meconium to induce severe MAS and were randomly treated with IT administration of captopril (0.5 mg/kg) (IT-Cap group, n = 6), or sham air instillation (Control group, n = 6). Cardiopulmonary profiles were monitored for a total of 5 h. Pulmonary history was examined to compare lung injury severity between groups.
Results: There were no significant differences between the two study groups in gas exchange and lung compliance, peak inspiratory pressure, heart rate, and mean arterial blood pressure over the 5 h experimental period, but there were trends toward lower blood pressure and pH in the IT-Cap group. Histopathological examinations revealed significantly higher lung injury scores in the dependent site of the control group than in the non-dependent site of the control group and both sites of the IT-Cap group.
Conclusions: Intratracheal captopril did not present significant beneficial effects on severe meconium-injured lungs within 5 h after injury. Further studies with different disease severities and dosing strategies are required before clinical application .
|
|---|
